ACROMETA GROUP LIMITED
(Company Registration No. 2015440003M)
(Incorporated in the Republic of Singapore)

ENTRY INTO AN INDICATIVE TERM SHEET IN RELATION TO THE PROPOSED INVESTMENT

---

1) INTRODUCTION

The Board of Directors (the "**Board**" or "**Directors**") of Acrometa Group Limited ("**Acrometa**", the "**Company**", and together with its subsidiaries, the "**Group**") wishes to announce that the Company has on 4 September 2026 entered a non-binding indicative term sheet (the "**Term Sheet**") with Macro HRD SG Pte. Ltd. ("**Macro**") (each a "**Party**", and collectively, the "**Parties**"). The Term Sheet sets out certain key understanding between the Macro and the Company, in respect of the Company's proposed investment (the "**Proposed Investment**") in Macro-ATCLS Pte Ltd., a company to be set up by Macro to commercialise its Ambient Temperature Cellular Logistics ("**ATCLS**") project.

The Term Sheet is only an indicative expression of intent by the parties relating to the Proposed Investment and does not create any legally binding nor enforceable obligations on the parties.

2) PROPOSED INVESTMENT

The Parties are desirous to work together in two areas, of which:

a. Acrometa securing the exclusive rights to ATCLS for the Territories (the "**Licensing Option**"); and
b. Acrometa taking a strategic stake in Macro-ATCLS and/or the ATCLS business.

Acrometa will have the exclusive option to acquire the licensing rights of the ATCLS business in the Territories. The Licensing Option will be for twelve (12) months unless mutually extended by the Parties.

The Territories will include the member states of Southeast Asia, namely Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines, Singapore, Thailand, Vietnam and Timor-Leste.

The actual terms of the Proposed Investment will be negotiated and agreed upon between the parties to the Term Sheet at the definitive agreement stage in respect of the Proposed Investment. It is intended that the definitive agreement will be entered into by no later than 30 Sep 2026 or such other dates as agreed between parties.

3) INFORMATION ON MACRO-ATCLS PTE LTD AND DETAILS OF PROPOSED PARTNERSHIP

Macro-ATCLS Pte Ltd is a company to be set up by Macro to commercialise its ATCLS project. Macro-ATCLS will own the intellectual property and the global licensing rights of the technology.

MACRO HRD SG Pte Ltd is a Singapore-based biotechnology and therapeutics company established in 2024, focused on developing scalable, precision-medicine solutions for high-burden infectious diseases with significant unmet medical needs. The company integrates advanced biology, therapeutic platform technologies and AI/ML-enabled decision systems to accelerate drug discovery and translational development from scientific research through clinical application. Its development portfolio includes innovative approaches targeting HIV/AIDS, HPV and other enveloped viruses, supported by proprietary therapeutic and drug-delivery platforms. Macro brings together an international network of scientific, clinical, regulatory, investment and technology expertise, with the mission of translating breakthrough science into novel therapeutics with meaningful global healthcare impact. [WCM: Please disclose names of the shareholders and directors of Macro HRD]

Ambient Temperature Cell Logistics (ATCLS) is an emerging technology licensed by Macro, designed to fundamentally transform the transportation and distribution of living cells and other temperature-sensitive biological materials by eliminating reliance on conventional refrigerated and cryogenic cold chains. ATCLS uses proprietary ambient-temperature preservation and reactivation technologies, supported by its proprietary **Gradient Equilibrium Decision Modeling (GEDM)** platform for real-time governance, chain-of-identity and process control, enabling dormant living cells to be transported at ambient temperature and reactivated at the point of use. The opportunity addresses rapidly expanding markets including stem cells, CAR-T/immune-cell therapy, gene therapy, regenerative medicine, organ and tissue transplantation, and cell-and-gene-therapy logistics; the underlying markets cited in the project materials range from **US$5.2 billion for immune-cell therapy to US$47 billion for organ transplantation**, while the global cell-and-gene-therapy 3PL market is estimated at **US$1.81 billion in 2025 and projected to reach US$16.95 billion by 2035 (25.1% CAGR)**. Based on defined ambient-addressable segments, ATCLS estimates a **Serviceable Addressable Market (SAM) of approximately US$14.5 billion by 2032**, positioning the technology as a potential category-creating solution capable of reducing the cost, fragility and geographic limitations of conventional cold-chain logistics. (See *Footnote 1*).

4) RATIONALE FOR THE PROPOSED INVESTMENT

The Group regards the proposed investment as an opportunity to broaden its business scope and achieve greater diversification.

5) INTERESTS OF DIRECTORS AND SUBSTANTIAL SHAREHOLDERS

As at the date of this announcement, save for their respective shareholdings in the Company (if any), none of the Directors and their respective associates, and to the best of knowledge of the Directors, none of the controlling shareholders of the Company and their respective associates has any interest, direct or indirect, in the Proposed Investment.

6) FURTHER ANNOUNCEMENTS

The Company will make further announcements in relation to the Proposed Investment, including but not limited to the assessment in compliance with Chapter 10 of the Catalist Rules, will be set out in the announcement to be made by the Company at the time the Definitive Agreement(s) relating to the Proposed Investment will be signed and/or when there are material developments.

7) DIRECTORS' RESPONSIBILITY STATEMENT

The Directors collectively and individually accept full responsibility for the accuracy of the information given in this announcement and confirm, after making all reasonable enquiries, that to the best of their knowledge and belief, this announcement constitutes full and true disclosure of all material facts about the Proposed Investment, the Company and its subsidiaries, and the Directors are not aware of any facts the omission of which would make any statement in this announcement misleading. Where information in this announcement has been extracted from published or otherwise publicly available sources or obtained from a named source, the sole responsibility of the Directors has been to ensure that such information has been accurately and correctly extracted from those sources and/or reproduced in the announcement in its proper form and context.

8) CAUTIONARY STATEMENT

Shareholders and potential investors of the Company are advised to read this announcement and any further announcements by the Company carefully. Shareholders and potential investors are advised to refrain from taking any action in respect of their securities in the Company which may be prejudicial to their interests and to exercise caution when dealing in the securities of the Company. In the event of any doubt, shareholders should consult their stockbrokers, bank managers. Solicitors, accountants or other professional advisers.

Footnote 1: This information was provided by Macro's management and has not been verified by the board of directors. The directors have not audited or verified the data supplied by the company.

BY ORDER OF THE BOARD

Toh Ker How
Executive Director
4 September 2026

---

*This announcement has been reviewed by the Company's Sponsor, W Capital Markets Pte. Ltd. (the "**Sponsor**"). This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**SGX-ST**"), and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.*

The contact person for the Sponsor is Mr Agustinus Suryanata, at 65 Chulia Street #43-01 OCBC Centre, Singapore 049513, telephone (65) 6513 3543.